Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMMIT
DRKS00004455Phase 2Terminated
- Sponsor
- EANM Research
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Medullary Thyroid Cancer (MTC) comparing Sorafenib with Placebo → Sorafenib (2 arms). Primary endpoints: Efficacy of sorafenib and Safety of sorafenib. Started Oct 2012; status: terminated.
02
Drugs
sorafenib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on DRKS00004455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004455.